CASE REPORT

Curative treatment in a patient with gastric cancer stage IV: a case report [version 1; peer review: 3 approved, 1 not approved]

Andreas Diel\textsuperscript{1,2}, Ernst Rodermann\textsuperscript{1,2}, Hans-Friedrich Kienzle\textsuperscript{3}, Denis Meuthen\textsuperscript{4}, Ingo Meuthen\textsuperscript{2,5}

\textsuperscript{1}Practice Network Rhein-Sieg, Hematology and Oncology, Troisdorf / Bonn / Bad Honnef, Germany
\textsuperscript{2}Department of Hematology and Oncology, Kliniken der Stadt Köln gGmbH, Krankenhaus Holweide, Germany
\textsuperscript{3}Clinic of Surgery, Kliniken der Stadt Köln gGmbH, Krankenhaus Holweide, Germany
\textsuperscript{4}Institute for Evolutionary Biology and Ecology, University of Bonn, Bonn, Germany
\textsuperscript{5}Practice of Internal Medicine, Hematology and Oncology, Cologne, Rodenkirchen, Germany

First published: 19 Oct 2012, 1:34
https://doi.org/10.12688/f1000research.1-34.v1

Abstract

A 39-year old patient with gastric adenocarcinoma stage IV failed to respond to preoperative chemotherapies containing 5-FU and cisplatin as well as 5-FU and irinotecan. After third-line chemotherapy with two cycles of docetaxel and cisplatin we confirmed a clinical partial response. A complete histologically confirmed remission was detected after complete resection of the tumor. Following two postoperative cycles of docetaxel and cisplatin, the tumor is still in complete remission after more than eight years.
Case report
In November 2003, a 39 year old male patient was diagnosed with a locally advanced gastric adenocarcinoma. The diagnosis and tumor stage were confirmed by gastroscopy, endoscopic ultrasound (EUS = u-staging), computer tomography (CT) scans of the thorax/abdomen and a bone scintigraphy. Gastroscopic biopsies revealed a Helicobacter pylori-negative gastric adenocarcinoma, diffuse type G3. According to the TNM/UICC staging system the carcinoma stage was cT4N3M0 or stage IV, respectively. We found an invasion of the colon transversum and more than sixteen significantly enlarged lymph nodes (Figure 1a). We did not test the Her-2-neu status in 2003. Multidisciplinary treatment planning included preoperative chemotherapy followed by operation and postoperative chemotherapy in curative intention. The patient suffered from a severe hypertensive cardiomyopathy, thus he was not eligible for an anthracycline containing chemotherapy.

After six weeks on PLF (cisplatin 50 mg/m² every two weeks, weekly folinic acid 500 mg/m² and 5-FU 2000 mg/m²/24h), we found no response. We changed to the FLI-regimen (weekly folinic acid 500 mg/m², 5-FU 2000 mg/m²/24h, irinotecan 80 mg/m²), there was no response after six weeks as well. After applying two cycles of DC (docetaxel 50 mg/m² d 1 + 15, cisplatin 50 mg/m² d 1 + 15, every four weeks), we detected a partial remission on endoscopy and abdominal CT (Figure 1b). In June 2004, a gastrectomy with a D2 lymph node dissection was performed resulting in a R0 status and a pathologically confirmed complete remission (CR). The patient was in good postoperative condition, he tolerated two further postoperative cycles of DC well without more than grade-2-toxicity. In September 2004, the patient underwent a laparotomy due to an acute bowel obstruction caused by adhesive bands after previous abdominal surgery. No carcinoma was detected macroscopically or histologically (Figure 1c). Up to this day, more than thirteen years after the diagnosis, the tumor is still in CR. The patient’s quality of life is not compromised in any way (ECOG performance status 0).

Using the TNM/UICC-classification of gastric cancer 2010, our patient would be classified as stage cT4bN3bM0, stage IIIc.

Discussion
The 5-year median overall survival rate for stage III and IV patients receiving perioperative chemotherapy is 39.1% and 5.2% after surgical resection alone\(^5,6\). Since 2010, the standard of care in locally advanced gastric cancer (uT3-T4) is three preoperative cycles of an anthracycin containing polychemotherapy like epirubicine, cisplatin and 5-FU (ECF) followed by three postoperative cycles. This kind of treatment improved 5-year survival from 23% with surgery alone to 36.3%\(^6,7\). There are no sufficient data from randomised phase III studies to strongly recommend perioperative chemotherapy for patients with uT2 carcinomas\(^8\).

Two preoperative cycles of PLF seem to be as effective as preoperative ECF\(^9,10\). In advanced gastric cancer, polychemotherapy offers a survival advantage over single-agent therapy. Comparing 5-FU/cisplatin-containing regiments with versus without anthracyclins and 5-FU/anthracyclin-containing combinations with or without cisplatin there is a significant survival benefit for 5-FU + anthracyclins + cisplatin. In this analysis, secondary resectability in locally advanced disease was not reported\(^11\).

In metastatic gastric adenocarcinomas and adenocarcinomas of the gastrooesophageal junction 5-FU can be substituted by capecitabine without compromising the results, so capecitabine may be used instead of 5-FU in the perioperative setting in combination with cisplatin (XP) or with epirubicine and cisplatin (ECX)\(^12,13\). In metastatic disease oxaliplatin has been tested as a substitute for cisplatin in combination chemotherapy with similar results\(^11,14\). The use of oxaliplatin can be recommended for patients suffering from renal insufficiency or patients with severe adverse events after cisplatin treatment\(^15\). Irinotecan or Docetaxel combinations have not been established for the perioperative treatment of gastric cancer in 2004. Both drugs were used in combinations for palliative therapy only\(^16,17\).

At the ASCO meeting in 2011 the FLOT3 trial\(^11\) has been presented:

Patients with untreated operable gastric adenocarcinoma received four preoperative cycles of FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) and underwent surgical resection (D2 resection) followed by four postoperative cycles. Patients with limited metastatic disease (distant intra-abdominal lymph nodes and/or a maximum of one organ involved in metastatic disease, ECOG-PS < 1) received eight cycles and underwent surgical resection when a complete macroscopic resection seemed possible. Surgical treatment was conducted

---

**Figure 1. Abdominal CT scans.** a) before treatment December 2003 b) after partial remission May 2004 c) after complete remission November 2005.
in 95.7% and 42.64% of the patients, respectively. For operable patients the median overall survival was not reached, for patients with limited disease the median overall survival was 18.6 months; there were also significant differences in progression-free survival (p < 0.001). Grade 3–4 toxicities were similar among the groups and occurred in 70.6% vs. 72.1% of the patients, respectively.

In gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction stage T2 a perioperative chemotherapy can be considered (Level of evidence 1b), in stage T3 and in resectable T4a adenocarcinomas patients should receive a pre- and postoperative polychemotherapy (Level of evidence 1b).

Our patient may be one of the rare cases with advanced gastric cancer cured by perioperative third line chemotherapy and surgery.

Consent
Written informed consent for publication of clinical details and clinical images was obtained from the patient.

Author contributions
IM found the case in his clinic. AD, ER, IM and HFK collected data. IM drafted the manuscript. DM reviewed the literature and revised the manuscript critically. All authors were involved in the revision of the draft manuscript and have agreed to the final content.

Competing interests
No competing interests were disclosed.

Grant information
The author(s) declared that no grants were involved in supporting this work.

References

1. Sobin LH, Wittekind C. TNM-classification of malignant tumors. 6th ed. New York: Springer 2002. Reference Source
2. Sobin LH, Gospodarowicz MK, Wittekind C, et al.: TNM-classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell 2010. Reference Source
3. Wang W, Li YF, Sun XW, et al.: Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer. 2010; 29(11): 923–930. PubMed Abstract | Publisher Full Text
4. Boige V, Pignon JP, Saint-Aubert JB, et al.: Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus. J Clin Oncol. 2007; 25(Suppl 18S): abstr 4510. Reference Source
5. Kelsen DP, Ginsberg R, Pajak TF, et al.: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998; 339(27): 1979–1984. PubMed Abstract | Publisher Full Text
6. Okines A, Verheij M, Allum W, et al.: Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2010; 21(Suppl 5): v52–54. PubMed Abstract | Publisher Full Text
7. Cunningham D, Allum WH, Stering SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1): 11–20. PubMed Abstract | Publisher Full Text
8. Moehler M, Al-Batran SE, Andus T, et al.: German S3-guideline “Diagnosis and treatment of esophagogastric cancer”. Z Gastroenterol. 2011; 49(4): 461–531. PubMed Abstract | Publisher Full Text
9. Schuhmacher C, Schlaf P, Lordick F, et al.: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardio: Randomized EORTC phase III trial 40954. J Clin Oncol. 2009; 27(Suppl 15S): abstr 4510. Reference Source
10. Schuhmacher C, Gretschel S, Lordick F, et al.: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardio: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol. 2010; 28(35): 5210–5218. PubMed Abstract | Publisher Full Text | Free Full Text
11. Wagner AD, Unverzagt S, Grothe W, et al.: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010; (3): CD004064. PubMed Abstract | Publisher Full Text
12. Kang YK, Kang WK, Shin DB, et al.: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009; 20(4): 666–673. PubMed Abstract | Publisher Full Text
13. Cunningham D, Starling N, Rao S, et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 359(1): 36–46. PubMed Abstract | Publisher Full Text
14. Okines AF, Norman AR, McCloud P, et al.: Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009; 20(9): 1529–1534. PubMed Abstract | Publisher Full Text
15. Al-Batran SE, Hartmann JT, Probst S, et al.: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008; 26(9): 1435–1442. PubMed Abstract | Publisher Full Text
16. Pozzo C, Bugat R, Peschel C, et al.: Irinotecan in combination with CDDP or 5-FU and folic acid is active in patients with advanced gastric or gastro-esophageal junction adenocarcinoma: Final results of a randomised phase II study. Proc Am Soc Clin Oncol. 2001; 20: abstr S31.
17. Roth AD, Maibach R, FALK S, et al.: Docetaxel-cisplatin-SFU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-SFU (ECP) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2004; 22(Suppl (14S) (July 15 Supplement)): abstr 4020. Reference Source
Open Peer Review

Current Peer Review Status:  ✔  ✔  ✔  ✗

**Version 1**

Reviewer Report 19 November 2012

https://doi.org/10.5256/f1000research.205.r331

© 2012 Schlag P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

[✗] Peter M Schlag
Charité Comprehensive Cancer Center, Charité Campus, Berlin, Germany

This is a single case report without any new information and is without any scientific background.

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Reviewer Report 14 November 2012

https://doi.org/10.5256/f1000research.205.r328

© 2012 Zafar S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

[✔] S Yousuf Zafar
Department of Medicine, Duke University Medical Center, Durham, NC, USA

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Ian Beales
School of Health Policy and Practice, University of East Anglia, Norwich, Norfolk, UK

The authors do discuss the FLOT3 trial at disproportionate detail compared to the rest of the discussion and probably a bit too excessively in response to the case reported. Whilst these data are interesting, it would be helpful to place these in a bit more context in relation to the case reported.

There are some typographical and grammatical errors in the Discussion section (pre-operative and insufficient data in the first paragraph).

The discussion about irinotecan and docetaxel combinations in the Discussion section: the authors could clarify whether they are primarily discussing the situation of current knowledge or as it stood in 2004. It would be most appropriate to discuss the current state of this combination in the article.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Maria Alsina Maqueda
Department of Medical Oncology, Medical Oncology, University Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

Overall, this case report is interesting and worthy of publication. There are however a few revisions that should be made:

1. In the Introduction section (2nd paragraph, 1st sentence), the chemotherapy scheme used in the patient is not the same as the one used by the study referenced; the scheme should be justified.

2. In the Introduction section (3rd paragraph, last sentence) there are more recent references to justify the classification statement (Thuss-Patiente Eur J Cancer 2011, Kang Clin Oncol 2012 and Van Cutsem ASCO GI 2012).
3. In the Discussion section (4th & 5th paragraphs) the authors refer to a study published in ASCO/JCO 2008, not 2011 which they have stated.

4. In the Discussion section (5th paragraph) the authors describe a study extensively with compared with the rest of the article, maybe authors should justify why (the use of docetaxel?).

5. The authors should discuss more extensively the use of the three lines with different efficacies in the neoadjuvant setting, and they should also address the issue of long gastric patient survivors.

6. In the Reference section, references 9 and 10 references refer to the same study; it is the newest one should appear, and the older one can be removed.

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com